Carlsmed, Inc.’s (NASDAQ:CARL) Lock-Up Period Will End on January 19th

Carlsmed’s (NASDAQ:CARL) lock-up period is set to end on Monday, January 19th. Carlsmed had issued 6,700,000 shares in its initial public offering on July 23rd. The total size of the offering was $100,500,000 based on an initial share price of $15.00. After the expiration of Carlsmed’s lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

Analysts Set New Price Targets

A number of research firms have recently commented on CARL. The Goldman Sachs Group reissued a “buy” rating and issued a $20.00 target price on shares of Carlsmed in a report on Friday, January 9th. Truist Financial reiterated a “buy” rating and set a $20.00 price objective (up from $18.00) on shares of Carlsmed in a research report on Friday, November 7th. Wall Street Zen upgraded shares of Carlsmed from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. BTIG Research reiterated a “buy” rating and set a $24.00 price target on shares of Carlsmed in a report on Monday, December 15th. Finally, Weiss Ratings reissued a “sell (e-)” rating on shares of Carlsmed in a report on Monday, December 22nd. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Carlsmed has a consensus rating of “Moderate Buy” and an average price target of $21.33.

Carlsmed Price Performance

NASDAQ:CARL opened at $13.54 on Friday. Carlsmed has a one year low of $11.45 and a one year high of $17.19. The company has a current ratio of 12.03, a quick ratio of 11.91 and a debt-to-equity ratio of 0.14. The firm has a market cap of $360.03 million and a P/E ratio of -4.05. The stock’s 50 day simple moving average is $13.31.

Carlsmed (NASDAQ:CARL) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.05.

Hedge Funds Weigh In On Carlsmed

Hedge funds have recently made changes to their positions in the stock. Zimmer Partners LP acquired a new position in shares of Carlsmed in the 3rd quarter worth approximately $670,000. Millennium Management LLC acquired a new stake in shares of Carlsmed during the third quarter worth $278,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of Carlsmed during the third quarter worth $42,000. Citadel Advisors LLC bought a new position in Carlsmed during the third quarter worth $1,473,000. Finally, Bank of America Corp DE acquired a new position in Carlsmed in the third quarter valued at $202,000.

Carlsmed Company Profile

We are a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. We are focused on becoming the standard of care for spine fusion surgery. The aprevo Technology Platform consists of artificial intelligence (“AI”)-enabled software solutions, and interbody implants that we custom design for each patient’s unique pathology and vertebral bone topography, and single-use surgical instruments (the “aprevo Technology Platform”).